Volume 8, Issue 1 (6-2021)                   vacres 2021, 8(1): 52-59 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hozouri H, Shamsian A, Aghasadeghi M, Doroud D. Comparative Study of AEFI of Hepatitis B Vaccine between Iran Ministry of Health CDC and VAERS Data during 2015 to 2017. vacres. 2021; 8 (1) :52-59
URL: http://vacres.pasteur.ac.ir/article-1-275-en.html
Viral Vaccine Research Center, Pasteur Institute of Iran, Tehran, Iran. Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran.
Abstract:   (246 Views)
Introduction: Hepatitis B Vaccine (HBV) is a safe and effective vaccine that is nowadays recommended for all infants at birth as well as adults who could be exposed to hepatitis B virus. HBV can provide lifetime protection against hepatitis B virus infection. Despite its highly effective disease prevention, HBV can also cause adverse effects for the vaccinated population. A vast majority of Iran's population are vaccinated with recombinant hepatitis B vaccine (rHBV) which is manufactured by the Production and Research Complex of Pasteur Institute of Iran. Methods:  The reported adverse events of rHBV, obtained from Diseases Management Center of Iran’s Ministry of Health were compared with those in The Vaccine Adverse Event Reporting System (VAERS, a United States program for vaccine safety, co-managed by the U.S. Centers for Disease Control and Prevention) during 2015 to 2017. Results: The most common adverse events after administration of rHBV, manufactured by Pasteur Institute of Iran was injection site reactions and no life threatening adverse event was observed. Conclusion: Despite reports by VAERS indicating that HBV can cause adverse events and even death in the United States, no such adverse effects were observed in rHBV manufactured in Iran.
Full-Text [PDF 1051 kb]   (78 Downloads)    
Type of Study: Research | Subject: Vaccine development, efficacy and safety evaluation
Received: 2022/01/3 | Accepted: 2021/06/30 | Published: 2022/04/3

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.